Ocular Therapeutix (NSDQ:OCUL) shares fell today on third-quarter results that narrowly topped the consensus forecast despite a bottom-line dip.
The Bedford, Mass.–based ophthalmic insert maker posted losses of -$18,778, or -45¢ per share, on sales of $829,000 for the three months ended Sept. 30, for a 25.1% bottom-line slide on sales growth of 66.5%.
Adjusted to exclude one-time items, earnings per share were also -45¢, 2¢ ahead of Wall Street, where analysts were looking for sales of $580,000.
Get the full story on our sister site Drug Delivery Business News.
